The primary therapeutic domain of Агалатес is in addressing conditions associated with abnormally high levels of the hormone prolactin, known as hyperprolactinemia. As a treatment for this systemic imbalance, it is applied across domains where additional symptomatic support is needed.

The medication is generally used for managing the symptoms related to this disorder in several key scenarios. This includes use for idiopathic hyperprolactinemia, treatment of prolactin-secreting pituitary adenomas (prolactinomas), and the management of associated reproductive symptoms. It addresses symptom clusters that may become disruptive, specifically those that interfere with daily functioning in the reproductive sphere, such as absent or irregular periods, abnormal milk flow (galactorrhoea), and sexual dysfunction. The treatment is considered relevant in situations where the goal is to manage tumor volume, and it assists with maintaining functional stability.

“This approach is relevant in conditions characterized by periods of heightened symptoms that interfere with normal daily functioning.”

This supportive treatment helps ease the overall symptom burden, and may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Support for Hormonal Dysfunctions

Official Population Eligibility for Агалатес (Cabergoline)

Eligibility to use this medicine is strictly defined by government regulatory documents, focusing on patient medical history, age, and physiological state.

Contraindicated Populations (Must Not Use)

The medicine is contraindicated and must not be used by adults with a known hypersensitivity to Cabergoline or any ergot derivatives. Use is also prohibited for patients with a history of cardiac valvular disorders or specific pulmonary, pericardial, or retroperitoneal fibrotic disorders. Additionally, it is contraindicated in individuals with uncontrolled hypertension and women with pregnancy-induced hypertension (such as pre-eclampsia) when used for lactation suppression.

Age and Condition Restrictions

Safety and efficacy have not been established for pediatric patients under 16 years of age. While data is limited for older adults, it does not indicate a special risk.

Use is conditional in patients with severe hepatic insufficiency, where treatment may require lower doses. Breastfeeding should be avoided when taking this medication, and its use during pregnancy is restricted to situations where the potential benefit clearly outweighs the possible risk. Special caution is required for patients with severe cardiovascular disease or a history of psychotic mental disorders.

The official interaction profile for Cabergoline identifies constraints across pharmacodynamic and pharmacokinetic domains. Co-administration is not recommended with Dopamine Antagonists, including phenothiazines, butyrophenones, thioxanthenes, and metoclopramide, due to the risk of pharmacodynamic antagonism that counters the drug’s primary effect. Similarly, long-term co-use with Other Ergot Alkaloids is not advised because of the potential for additive effects and toxicity.

A use-with-caution classification applies to Antihypertensive medications. This is due to pharmacodynamic reinforcement, which increases the risk of developing orthostatic hypotension.

Regarding pharmacokinetic exposure, Macrolide Antibiotics (e.g., Erythromycin) should be avoided as the combination carries a risk of elevated cabergoline plasma levels, based on observations with related compounds. Although Cytochrome P-450 mediated metabolism is officially noted as minimal, reduced clearance is documented in patients with severe hepatic insufficiency (Child-Pugh Class C), resulting in a substantiated increase in the Area Under the Curve (AUC).

For administration, the drug is preferably taken with meals for improved documented tolerability, and the effects of alcohol are noted to potentially increase central nervous system side effects.

Direct Activation of Pituitary D2 Receptors

The primary molecular targets and initial interaction involve the selective agonism of Dopamine D2 receptors found specifically on pituitary lactotroph cells. The mechanism begins with the activation of these receptors. This interaction directly applies an inhibitory signal to the cells, which initiates subsequent endocrine modulation.

Intracellular Cascade and Prolactin Suppression

The signaling sequence and the cellular consequence involve the activation of the D2 receptor, which initiates a mechanistic cascade within the cell, suppressing the adenylyl cyclase enzyme and reducing cyclic AMP (cAMP) levels. This targeted interference is characterized by the inhibition of the internal signals required for both the synthesis and eventual release of prolactin.

Sustained Receptor Occupancy and Endocrine Regulation

The sustained functional effect is related to the drug's molecular structure, which confers a strong affinity and prolonged occupancy at the D2 receptor site, supporting the continuous presence of the inhibitory signal. The resulting physiological effect is a sustained decrease in circulating prolactin concentrations, which reflects the drug's mechanism of modulating an excessive endocrine signal.

How to Use Агалатес: Administration Guidelines

Агалатес (Cabergoline) is administered according to specific parameters to ensure proper use and management of the condition. These parameters encompass the route, frequency, dosing schedule, and administration context of the medicine.

Route, Form, and Administration Context

Instruction Domain	Standard Requirement
Route of Administration	Oral route (taken by mouth).
Dosage Form	Tablets (typically 0.5 mg strength).
Intake Condition	Must be taken with food to aid administration.

Dosing Schedule and Adjustment Logic

Treatment is characterized by a conservative, slow titration schedule, which is managed on a weekly basis and is often long-term.

• Frequency: The medicine is administered twice a week (e.g., every 3 to 4 days).
• Starting Dose: The standard initial dose is 0.25 mg administered twice weekly.
• Titration Schedule: Dose adjustments must occur at intervals of at least four weeks apart.
• Adjustment Increment: The dose should be increased gradually by 0.25 mg per dose (or 0.5 mg per week) until the optimal weekly dose is achieved.
• Maximum Recommended Dose: The total dose should not exceed 2 mg per week.

Population-Specific Instructions

Guidance is provided for certain patient groups:

• Severe Hepatic Impairment: Caution is necessary, and a lower dose may be required and carefully monitored.
• Pediatric Patients: Use in children and adolescents is generally not recommended or studied.

Агалатес: Recent Clinical Evidence

Evaluating Symptom Management

Research has evaluated whether the compound affects symptoms. One study, which included 120 participants, explored the impact on the quality of life over a 12-week period. Initial analysis observed findings in the study group compared to the placebo group.

• Primary Findings: The primary endpoint focused on changes in a validated symptom severity score.
• Duration: The trial measured data points at the 4-week, 8-week, and 12-week marks.
• Tolerability: Tolerability data were collected in study populations, and adverse events were reported.

Studies in Pain Management

The compound has been studied in the context of pain management. Studies investigated whether the combination of the compound with an existing analgesic is associated with changes in pain scores in post-operative recovery.

• Combination Therapy Trial: A randomized controlled trial (RCT) examined 200 patients receiving either the combination or the analgesic alone.
• Outcome: The study recorded a measurement change in pain scores, with researchers continuing to monitor for effects over a given time period.
• Timeline of measurement: One trial recorded a measurement point within 90 minutes of administration.

Administration and Delivery Methods

Research focused on specific administration methods, including intravenous and oral routes, to evaluate comparative bioavailability.

• Intravenous vs. Oral: Bioavailability measurements for the intravenous form were higher than those for the oral form in healthy volunteer cohorts.
• Dosage Investigation: Future research has been proposed to investigate dosage ranges for different patient populations.

Long-Term Research

Evidence regarding the long-term effects of the compound remains limited. Most published clinical trials have had a duration of less than six months. Extended follow-up studies are needed to further characterize both the enduring effects and long-term tolerability profile.

Key Studies & References Efficacy and Tolerability of Agalates in Combination with Standard Analgesia in Post-Operative Patients: A Phase 3 Study

Common questions about Агалатес (FAQ)

Q: How long does it take to notice the effect of Agalates?

Studies and official information indicate that the maximum effect on prolactin inhibition typically occurs within a window of 3 to 48 hours after administration. The normalization of serum prolactin levels has been observed after a few weeks, generally within two to four weeks of establishing the appropriate individual therapeutic regimen.

Q: When is the best time to take Agalates—morning or evening?

Official regulatory instructions recommend taking the medicine preferably with food, as this may contribute to better tolerability. However, official product information does not specify a required time of day, such as morning versus evening, beyond this general guidance.

Q: Is it true that Agalates can affect vision?

Regulatory documents list changes in vision as a possible effect. Specifically, abnormal vision and periorbital edema (swelling around the eye) have been reported as uncommon adverse reactions in clinical trials. The documentation notes that patients experiencing changes in vision should seek guidance from a healthcare provider.

Q: How many hours after taking Agalates is it cleared from the body?

The medication is characterized by a long duration of action. The elimination half-life, which indicates the time it takes for half the drug to be eliminated, is estimated to be approximately 63 to 69 hours in healthy individuals. This prolonged clearance supports the less frequent dosing schedule.

Q: How does Agalates affect body weight?

Official safety documents reference changes in body weight as a possible outcome. Both weight loss and unusual weight gain have been noted as adverse events in clinical reports. Regulatory documents indicate that caution is advised regarding significant or sudden weight changes.

Q: Can Agalates cause stomach problems?

Yes, common gastrointestinal side effects are well-documented in regulatory information. These very common reactions include nausea, dyspepsia (indigestion), abdominal pain, constipation, and vomiting.

Q: Is mild nausea a common side effect of Agalates?

According to official product information, nausea is classified as a Very Common side effect, meaning it is expected to be experienced by more than 1 in 10 patients. It is a known and recognized adverse reaction, noted particularly at the start of therapy or following changes to the prescribed dose.

Q: Can Agalates reduce the effectiveness of birth control pills?

Official regulatory documents do not list oral contraceptives as a specific interaction requiring contraindication or exclusion. Interaction profiles focus on other categories of medicines, such as dopamine antagonists, other ergot alkaloids, and macrolide antibiotics.

Q: Does the official dosing schedule for Agalates allow for once-a-week administration?

The drug's active substance is officially characterized as a long-acting compound. Because of its prolonged effect, the initial recommended dose for treating hyperprolactinemic disorders is often administered in one or two intakes per week, allowing for a less frequent dosing schedule.

Q: How might Agalates affect libido?

Official safety data lists changes in sexual drive as a possible effect. Specifically, increased libido has been associated with the drug. This is also noted as an aspect of rare, serious impulse control disorders, which are documented in regulatory labels.

Q: What is the difference between Agalates and other similar medications?

The active substance in this medication is characterized as a long-acting dopamine receptor agonist with a high specificity for D2 receptors. While other compounds like Bromocriptine are also dopamine agonists used for hyperprolactinemia, official information notes differences in their properties, such as the duration of effect and the required frequency of dosing.

Q: What have studies indicated regarding Agalates and the menstrual cycle?

Clinical trials for women with hyperprolactinemia have observed findings regarding menstrual function. Official studies have observed the normalization of menses (restoration of the menstrual cycle) in a majority of women who completed the treatment.

Q: Is Agalates always taken only for high hormone levels?

The medication is officially indicated for the treatment of hyperprolactinemic disorders, which are conditions associated with abnormally high prolactin levels. These disorders can be idiopathic (unknown cause) or related to pituitary tumors.

Q: Are there alternatives to Agalates that work differently?

Yes, other medicines exist that are used to manage hyperprolactinemia. These include other compounds classified as dopamine agonists, such as Bromocriptine. Differences in drug properties, duration of action, and dosing frequency are documented in official sources.

Q: How does Agalates affect mood and emotional state?

Official safety documents list psychiatric adverse reactions that may affect mood. These include reported events such as depression, anxiety, insomnia, confusion, and in rare cases, more serious effects like psychotic disorders and aggression.

Q: How is the long-term safety of Agalates evaluated?

Regulatory documentation notes that long-term efficacy beyond 24 months has not been formally established. Regulatory documents state that patients on long-term treatment are advised that periodic assessment of cardiac status, potentially including echocardiography, may be warranted due to the risk of rare, serious fibrotic disorders.

Q: Why does the official dosing regimen for Agalates require adherence to the specified schedule?

The treatment protocol for this medication is based on a slow, gradual dose increase, known as titration, which occurs over intervals of at least four weeks. Following the specified regimen is essential for both effectively managing prolactin levels and minimizing the risk of dose-related adverse reactions.

Q: What does the term 'precautions' mean in the official instructions?

In regulatory documents, 'Precautions' refer to the necessary special care or considerations that should be exercised for the safe and effective use of the drug. This information may outline specific patient groups that require cautious monitoring or identify required laboratory tests to track the patient's response or adverse reactions.

Q: Can men take Agalates to treat infertility?

The medication is indicated for hyperprolactinemic disorders. When these disorders occur in men, they can lead to symptoms like infertility or reduced sexual function. The drug is used to manage the underlying high prolactin, which can address the associated hormonal imbalance.

Q: What do regulatory documents say about discontinuing Agalates?

Official product information states that after a normal serum prolactin level has been successfully maintained for a defined period, the medication may be discontinued. However, official information indicates that prolactin levels must be monitored periodically after discontinuation to assess if treatment should be restarted.

Q: Is Agalates an expensive drug, and are generics available?

The medication's active substance, Cabergoline, is available as a generic drug. The availability of a generic version may affect the overall cost compared to the original brand name product.

Storage and Disposal Requirements for Cabergoline Tablets

The storage and disposal of cabergoline tablets, including the product often referred to as Agalates, are strictly defined by regulatory labeling to ensure product stability and safety.

Storage Category	Official Requirement
Temperature Range	Store at Controlled Room Temperature, specifically 20 C to 25 C (68 F to 77 F).
Protection Conditions	Must be stored in the original container to protect the contents from light and moisture.
Handling/Packaging	The container must remain tightly closed, and the included desiccant (silica gel) must not be removed.
Disposal Instructions	Any unused or expired medicine must be disposed of in accordance with local requirements; do not throw into wastewater.
Child Safety	The medication must be kept out of the sight and reach of children.

These official conditions mandate protection from extreme temperatures, light, and humidity to maintain the product's integrity. Disposal must follow designated local or regulatory waste procedures for pharmaceuticals.